These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38462547)

  • 1. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.
    Kishk OA; Kim I; Cheng C; Summan M; Muñoz MA
    Pediatr Nephrol; 2024 Aug; 39(8):2429-2433. PubMed ID: 38462547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
    Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
    J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
    Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
    Langman CB
    Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules.
    Pavloff N; Hauser TA; Williams C; Isbell SL; Cadieux B; Johnson M
    Drug Des Devel Ther; 2018; 12():2795-2804. PubMed ID: 30233142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.
    FitzSimmons SC; Burkhart GA; Borowitz D; Grand RJ; Hammerstrom T; Durie PR; Lloyd-Still JD; Lowenfels AB
    N Engl J Med; 1997 May; 336(18):1283-9. PubMed ID: 9113931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
    Dohil R; Cabrera BL
    Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
    Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
    Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosing Colonopathy Presenting in a Patient with Cystinosis.
    Fiore D; Sohini V; Mileti E; Fiore N
    JPGN Rep; 2023 Aug; 4(3):e321. PubMed ID: 37600607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
    Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
    JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosing colonopathy in children with cystic fibrosis.
    Reichard KW; Vinocur CD; Franco M; Crisci KL; Flick JA; Billmire DF; Schidlow DV; Weintraub WH
    J Pediatr Surg; 1997 Feb; 32(2):237-41; discussion 241-2. PubMed ID: 9044129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.